Gynecologic Cancers (Issue 1)

Maurie Markman, MD, discusses the role of molecular testing in gynecologic cancers.

Mary-Claire King, PhD, the researcher who identified BRCA1's linkage to hereditary breast and ovarian cancer, was announced as the winner of the 2014 Lasker~Koshland Special Achievement Award in Medical Science.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses trabectedin as a potential agent to treat ovarian cancer.

Stand Up To Cancer (SU2C) recently announced the launch of a new Ovarian Cancer Dream Team.

Most patients with ovarian cancer present with bulky and metastatic disease. Surgery and platinum-based chemotherapies are the mainstay of treatment for newly diagnosed disease, but recurrence/resistance are common.

Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.

The cobas HPV Test was approved in 2014 by the FDA as a primary tool for cervical cancer screening in women ≥25 years of age, highlighting the need for updated guidelines to direct the use of approved screening methods in clinical practice.

Richard T. Penson, MD, Bradley J. Monk, MD, and Krishnansu S. Tewari, MD, weigh in on the changing landscape of the treatment of cervical cancer.